Market trends · on the rundown Wednesday, March 25, 2026
Hope Medicine Doses First Phase III Patient for Non-Hormonal Endometriosis Drug
Covered by 13 outlets over 1 hour. All of them ran the same syndicated report. First reported by woonsocketcall.com at 00:08 UTC on March 25, 2026.
- outlets13
- distinct reports1
- first to latest report1 h
- names in it3
What happened?
- The Phase III trial is a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
- The FDA has granted HMI-115 Fast Track Designation for moderate-to-severe endometriosis pain.
- China's NMPA/CDE has awarded the drug Breakthrough Therapy Designation.
- Phase II results published in The Lancet showed significant pain reduction without menopausal side effects.
A machine summary written from the reports listed below; read them for the full account. How summaries are made and what is checked.
Who reported it, and when?
| Time | Report | Run by |
|---|---|---|
| Mar 25 00:08 | Report by woonsocketcall.com |
A report's title is shown once our automated legal check has read it and passed it; these reports are named by outlet, and the links lead to each report.
Who was named?
More news naming National Medical Products Administration (NMPA)
- Jul 17 · Healthcare China's BCI sector advances toward industrialisation, report says 1
- Jun 23 · Biotech China clinical drug trial registrations hit record in 2025, regulator says 1
- Mar 19 · Space & defense russiaherald.com (Big News Network): “Column: Xi vision and China 15th Five - Year Plan” 1
- Mar 12 · Legal China aims to lead in tech rather than catch up with US, CNN reports 1
- Mar 7 · Legal China to accelerate tech self-reliance during 15th Five-Year Plan period 1
- Mar 6 · PropTech China details 2026 policy mix to bolster growth and innovation 2
Sources: the outlets' reports linked on this page; counts and times from GetYourBrief's record of those reports (methodology).